Specific immunotherapy for allergic diseases
Keywords:
Specific immunotherapy, allergic diseases
Abstract
Specific allergen immunotherapy (SIT)involves the administration of allergen
extracts to modify or abolish symptoms
associated with atopic allergy. The process is
specific, in that the treatment is targeted at those
allergens recognized by the patient and physician as
responsible for symptoms. A decision to use SIT
therefore demands a careful assessment of the patient’s
condition and the role of allergic triggers.
Immunotherapy was first developed at St Mary’s
Hospital, London at the end of the 19th century, and
many of the basic principles remain valid today.
References
1. Freeman J. Vaccination against hay fever: report of re-
sults during the first three years. Lancet 1914;1:1178.
2. Creticos PS, Van Metre TE, Mardiney MR, Rosenberg
GL, Norman PS, Adkinson NF. Dose-response of IgE
and IgG antibodies during ragweed immunotherapy. J
Allergy Clin Immunol 1984;73:94-104
3. Iliopoulos O, Proud D, Adkinson NF, Creticos PS,
Norman PS, Kagey-Sobotka A, et al. Effects of immu-
notherapy on the early, late and rechallenge nasal re-
action to provocation with allergen: changes in inflam-
matory mediators and cells. J Allergy Clin Immunol
1991;87:855-66.
4. Durham SR, Ying S, Varney VA, Jacobson MR,
Sudderick RM, Mackay IS, et al. Grass pollen immu-
notherapy inhibits allergen-induced infiltration of
CD4+ T-lymphocytes and eosinophils in the nasal
mucosa and increases the number of cells expressing
mRNA for interferon-gamma. J Allergy Clin Immunol
1996;97:1356-65.
5. McHugh SM, Deighton J, Stewart AG, Lachmann PJ,
Ewan PW. Bee venom immunotherapy induces a shift
in cytokine responses from a Th2 to a Th1 dominant
pattern: Comparison of rush and conventional immu-
notherapy. Clin Exp Allergy 1995;25:828-38.
6. Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann
U, Schenk S, et al. Immunological changes during spe-
cific immunotherapy of grass pollen allergy: Reduced
lymphoproliferative responses to allergen and shift from
Th2 to Th1 in T-cell clones specific for Phl p1, a major
grass pollen allergen. Clin Exp Allergy 1997;27:1007-15.
7. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop
J, Saloga J. Insect venom immunotherpay induces IL-
10 production and a Th2 to Th1 shift, and changes
surface marker expression in venom-allergic subjects.
Eur J Immunol 1997;27:586-96.
8. Nasser SM, Ying S, Meng Q, Kay AB, Ewan PW. IL-10
levels increase in cutaneous biopsies of patients un-
dergoing wasp venom immunotherapy. Eur J Immunol
2001;31:3704-13.
9. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K.
Role of IL-10 in specific immunotherapy. J Clin Invest
1998;102:98-106.
10. Harsono A. Modulation of immune response in long-
term use of corticosteroid inhalation in childhood
asthma receiving immunotherapy [Dissertation].
Surabaya, Indonesia: Airlangga University: 2004.
11. Bellinghausen I, Knop J, Saloga J. The role of IL-10 in
the regulation of allergic immune responses. Int Arch
Allergy Appl Immunol 2001;126:97-101.
12. Guerra F, Carracedo J, Solana-Lara R, Sánchez-Guijo
P, RamÃrez. T H 2 lymphocytes from atopic patients
treated with immunotherapy undergo rapid apoptosis
after culture with specific allergens. J Allergy Clin
Immunol 2001;107:647-53
13. Golden DB, Marsh DG, Freidhoff LR, Kwiterovich KA,
Addison B, Kagey-Sobotka A, et al. Natural history of
hymenoptera venom sensitivity in adults. J Allergy Clin
Immunol 1997;100:760-6.
14. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB,
Durham SR. Usefulness of immunotherapy in patients
with severe summer hay fever uncontrolled by anti-
allergic drugs. Br Med J 1991;302:265-9.
15. Durham SR, Walker SM, Varga EM, Jacobson MR,
O’Brien F, Nobel W, et al. Long-term clinical efficacy
of grass pollen immunotherapy. N Engl J Med
1999;341:468-75.
16. Naclerio RM, Proud D, Moylan B, Balcer S,
Freidhoff L, Kagey-Sobotka A, et al. A double blind
study of the discontinuation of ragweed immuno-
therapy. J Allergy Clin Immunol 1997; 100:293-
300.
17. Varney VA, Edwards J, Tabbah K, Brewster H,
Mavroleon G, Frew AJ. Clinical efficacy of specific
immunotherapy to cat dander: A double blind placebo
controlled trial. Clin Exp Allergy 1997;27:860-7.
18. Bousquet J, Lockey RF, Malling HJ. WHO position
paper. Allergen immunotherapy: therapeutic vaccines
for allergic disease. Allergy 1998;53(S44):1-42.
19. Abramson M, Puy R, Weiner J. Immunotherapy in
asthma: an updated systematic review. Allergy
1999;54:1022-41.
20. Creticos PS, Reed CE, Norman PS, Khoury J, Adkinson
NF, Buncher CR, et al. Ragweed immunotherapy in
adult asthma. N Engl J Med 1996;334:501-6.
21. Lilja G, Sundin B, Graff-Lonnevig V, Hedlin G,
Heilborn H, Norrlind K, et al. Immunotherapy with
partially purified and standardised animal dander ex-
tracts. IV. Effects of 2 years of treatment. J Allergy Clin
Immunol 1989;83:37-44.
22. Adkinson NF, Eggleston PA, Eney D, Goldstein EO,
Schuberth KC, Bacon JR, et al. A controlled trial of
immunotherapy for asthma in allergic children. N Engl
J Med 1997;336:324-31.
23. Horak F. Manifestation of allergic rhinitis in latent sensi-
tized patients. A prospective study. Arch Otorhinolaryngol
1985;242:242-9.
24. Johnstone DE, Dutton A. The value of hyposensitiza-
tion therapy for bronchial asthma in children: a 14 year
study. Pediatrics 1968;42:793-802.
25. Des Roches A, Paradis L, Menardo JL, Bouges S,
Daures JP, Bousquet J. Immunotherapy with a
standardised Dermatophagoides pteronyssinus extract.
VI. Specific immunotherapy prevents the onset of new
sensitisations in children. J Allergy Clin Immunol
1997;99:450-3.
26. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A,
Jacobsen L, et al. Pollen immunotherapy reduces the
development of asthma in children with seasonal
rhinoconjunctivitis (the PAT-study). J Allergy Clin
Immunol 2002;109:251-6.
27. Shaikh WA. Immunotherapy vs inhaled budesonide
in bronchial asthma: An open parallel comparative
trial. Clin Exp Allergy 1997;27:1279-84.
28. Committee on the Safety of Medicines. CSM update:
immunotherapy. Br Med J 1986;293:948.
29. Stewart GE, Lockey RF. Systemic reactions from aller-
gen immunotherapy. J Allergy Clin Immunol 1992;
90:567-78.
30. Harsono A. Efficacy of low dose sub-lingual immuno-
therapy in the treatment of childhood asthma. Fol Med
Indones 2003;39:223-7.
31. Malling HJ, Abreu-Nogueira J, Alvarez-Cuesta E,
Bjorksten B, Bousquet J, Caillot D, et al. Local immu-
notherapy. Allergy 1998;53:933-44.
32. Lewith GT, Watkins AD, Hyland ME, Shaw S,
Broomfield JA, Dolan G, et al. Use of Ultra-molecular
potencies of allergen to treat asthmatic people allergic
to house dust mite. Br Med J 2002;324:520.
sults during the first three years. Lancet 1914;1:1178.
2. Creticos PS, Van Metre TE, Mardiney MR, Rosenberg
GL, Norman PS, Adkinson NF. Dose-response of IgE
and IgG antibodies during ragweed immunotherapy. J
Allergy Clin Immunol 1984;73:94-104
3. Iliopoulos O, Proud D, Adkinson NF, Creticos PS,
Norman PS, Kagey-Sobotka A, et al. Effects of immu-
notherapy on the early, late and rechallenge nasal re-
action to provocation with allergen: changes in inflam-
matory mediators and cells. J Allergy Clin Immunol
1991;87:855-66.
4. Durham SR, Ying S, Varney VA, Jacobson MR,
Sudderick RM, Mackay IS, et al. Grass pollen immu-
notherapy inhibits allergen-induced infiltration of
CD4+ T-lymphocytes and eosinophils in the nasal
mucosa and increases the number of cells expressing
mRNA for interferon-gamma. J Allergy Clin Immunol
1996;97:1356-65.
5. McHugh SM, Deighton J, Stewart AG, Lachmann PJ,
Ewan PW. Bee venom immunotherapy induces a shift
in cytokine responses from a Th2 to a Th1 dominant
pattern: Comparison of rush and conventional immu-
notherapy. Clin Exp Allergy 1995;25:828-38.
6. Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann
U, Schenk S, et al. Immunological changes during spe-
cific immunotherapy of grass pollen allergy: Reduced
lymphoproliferative responses to allergen and shift from
Th2 to Th1 in T-cell clones specific for Phl p1, a major
grass pollen allergen. Clin Exp Allergy 1997;27:1007-15.
7. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop
J, Saloga J. Insect venom immunotherpay induces IL-
10 production and a Th2 to Th1 shift, and changes
surface marker expression in venom-allergic subjects.
Eur J Immunol 1997;27:586-96.
8. Nasser SM, Ying S, Meng Q, Kay AB, Ewan PW. IL-10
levels increase in cutaneous biopsies of patients un-
dergoing wasp venom immunotherapy. Eur J Immunol
2001;31:3704-13.
9. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K.
Role of IL-10 in specific immunotherapy. J Clin Invest
1998;102:98-106.
10. Harsono A. Modulation of immune response in long-
term use of corticosteroid inhalation in childhood
asthma receiving immunotherapy [Dissertation].
Surabaya, Indonesia: Airlangga University: 2004.
11. Bellinghausen I, Knop J, Saloga J. The role of IL-10 in
the regulation of allergic immune responses. Int Arch
Allergy Appl Immunol 2001;126:97-101.
12. Guerra F, Carracedo J, Solana-Lara R, Sánchez-Guijo
P, RamÃrez. T H 2 lymphocytes from atopic patients
treated with immunotherapy undergo rapid apoptosis
after culture with specific allergens. J Allergy Clin
Immunol 2001;107:647-53
13. Golden DB, Marsh DG, Freidhoff LR, Kwiterovich KA,
Addison B, Kagey-Sobotka A, et al. Natural history of
hymenoptera venom sensitivity in adults. J Allergy Clin
Immunol 1997;100:760-6.
14. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB,
Durham SR. Usefulness of immunotherapy in patients
with severe summer hay fever uncontrolled by anti-
allergic drugs. Br Med J 1991;302:265-9.
15. Durham SR, Walker SM, Varga EM, Jacobson MR,
O’Brien F, Nobel W, et al. Long-term clinical efficacy
of grass pollen immunotherapy. N Engl J Med
1999;341:468-75.
16. Naclerio RM, Proud D, Moylan B, Balcer S,
Freidhoff L, Kagey-Sobotka A, et al. A double blind
study of the discontinuation of ragweed immuno-
therapy. J Allergy Clin Immunol 1997; 100:293-
300.
17. Varney VA, Edwards J, Tabbah K, Brewster H,
Mavroleon G, Frew AJ. Clinical efficacy of specific
immunotherapy to cat dander: A double blind placebo
controlled trial. Clin Exp Allergy 1997;27:860-7.
18. Bousquet J, Lockey RF, Malling HJ. WHO position
paper. Allergen immunotherapy: therapeutic vaccines
for allergic disease. Allergy 1998;53(S44):1-42.
19. Abramson M, Puy R, Weiner J. Immunotherapy in
asthma: an updated systematic review. Allergy
1999;54:1022-41.
20. Creticos PS, Reed CE, Norman PS, Khoury J, Adkinson
NF, Buncher CR, et al. Ragweed immunotherapy in
adult asthma. N Engl J Med 1996;334:501-6.
21. Lilja G, Sundin B, Graff-Lonnevig V, Hedlin G,
Heilborn H, Norrlind K, et al. Immunotherapy with
partially purified and standardised animal dander ex-
tracts. IV. Effects of 2 years of treatment. J Allergy Clin
Immunol 1989;83:37-44.
22. Adkinson NF, Eggleston PA, Eney D, Goldstein EO,
Schuberth KC, Bacon JR, et al. A controlled trial of
immunotherapy for asthma in allergic children. N Engl
J Med 1997;336:324-31.
23. Horak F. Manifestation of allergic rhinitis in latent sensi-
tized patients. A prospective study. Arch Otorhinolaryngol
1985;242:242-9.
24. Johnstone DE, Dutton A. The value of hyposensitiza-
tion therapy for bronchial asthma in children: a 14 year
study. Pediatrics 1968;42:793-802.
25. Des Roches A, Paradis L, Menardo JL, Bouges S,
Daures JP, Bousquet J. Immunotherapy with a
standardised Dermatophagoides pteronyssinus extract.
VI. Specific immunotherapy prevents the onset of new
sensitisations in children. J Allergy Clin Immunol
1997;99:450-3.
26. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A,
Jacobsen L, et al. Pollen immunotherapy reduces the
development of asthma in children with seasonal
rhinoconjunctivitis (the PAT-study). J Allergy Clin
Immunol 2002;109:251-6.
27. Shaikh WA. Immunotherapy vs inhaled budesonide
in bronchial asthma: An open parallel comparative
trial. Clin Exp Allergy 1997;27:1279-84.
28. Committee on the Safety of Medicines. CSM update:
immunotherapy. Br Med J 1986;293:948.
29. Stewart GE, Lockey RF. Systemic reactions from aller-
gen immunotherapy. J Allergy Clin Immunol 1992;
90:567-78.
30. Harsono A. Efficacy of low dose sub-lingual immuno-
therapy in the treatment of childhood asthma. Fol Med
Indones 2003;39:223-7.
31. Malling HJ, Abreu-Nogueira J, Alvarez-Cuesta E,
Bjorksten B, Bousquet J, Caillot D, et al. Local immu-
notherapy. Allergy 1998;53:933-44.
32. Lewith GT, Watkins AD, Hyland ME, Shaw S,
Broomfield JA, Dolan G, et al. Use of Ultra-molecular
potencies of allergen to treat asthmatic people allergic
to house dust mite. Br Med J 2002;324:520.
Published
2016-10-10
How to Cite
1.
Harsono A. Specific immunotherapy for allergic diseases. PI [Internet]. 10Oct.2016 [cited 19Apr.2024];45(4):137-4. Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/820
Section
Review Article
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Received 2016-10-06
Accepted 2016-10-06
Published 2016-10-10
Accepted 2016-10-06
Published 2016-10-10
